Gapping down
In reaction to disappointing earnings/guidance: ARTX -19.6%, YOD -12.4%, CUI -9.1%, (light volume), ROSG -8.6%, KGJI -3%, (light volume), XON -1.1%.
Other news: USU -12.9% (still checking; may be attributed to Japan's Hokkaido Electric Power considering Government bailout), MDCO -9.2% (provides update on Angiomax patent litigation), BIOF -7.4% (modestly pulling back), MDR -4.1% (provides an operational update; files for mixed securities shelf offering; announces public offering of 10 mln tangible equity units, each with a stated value of $25), KNDI -4% (unfavorable commentary on Mad Money), CSIQ -3.1% (receives CAD50.5 mln in financing from Manulife ), DEO -1.3% (still checking), GSK -1.2% (planning to expand in Africa, according to reports out), UN -1% (still checking), QCRH -0.9% (announces redemption of $15 mln of small business lending fund preferred stock), ICLD -0.8% (filed to delay from 10-K), CAT-0.8% (exec to testify before U.S. Senate subcommittee regarding co's business structure), KIN -0.7% (announces launch of $50 mln public offering of common stock),' GALT -0.7% (First cohort results in Galectin Therapeutics' Phase 1 trial reveal biomarker evidence of therapeutic effect on fibrosis and inflammation in NASH with advanced fibrosis), MHR -0.7% (files for 4.3 mln share common stock offering by selling shareholders), GM -0.3% (General Motors recalls older model vehicles to fix power steering; expects to take a charge of up to ~$750 mln in the first quarter, primarily for the cost of recall-related repairs).
Analyst comments: INVN -5.8% (downgraded to Perform at Oppenheimer), CLI -2.1% (downgraded to Hold from Buy at KeyBanc), MX -1.7% (downgraded to Neutral at Chardan Capital Markets), BGC -0.8% (downgraded to Neutral from Buy at DA Davidson), POT -0.6% (downgraded to Hold from Buy at Cantor Fitzgerald)
Other news: USU -12.9% (still checking; may be attributed to Japan's Hokkaido Electric Power considering Government bailout), MDCO -9.2% (provides update on Angiomax patent litigation), BIOF -7.4% (modestly pulling back), MDR -4.1% (provides an operational update; files for mixed securities shelf offering; announces public offering of 10 mln tangible equity units, each with a stated value of $25), KNDI -4% (unfavorable commentary on Mad Money), CSIQ -3.1% (receives CAD50.5 mln in financing from Manulife ), DEO -1.3% (still checking), GSK -1.2% (planning to expand in Africa, according to reports out), UN -1% (still checking), QCRH -0.9% (announces redemption of $15 mln of small business lending fund preferred stock), ICLD -0.8% (filed to delay from 10-K), CAT-0.8% (exec to testify before U.S. Senate subcommittee regarding co's business structure), KIN -0.7% (announces launch of $50 mln public offering of common stock),' GALT -0.7% (First cohort results in Galectin Therapeutics' Phase 1 trial reveal biomarker evidence of therapeutic effect on fibrosis and inflammation in NASH with advanced fibrosis), MHR -0.7% (files for 4.3 mln share common stock offering by selling shareholders), GM -0.3% (General Motors recalls older model vehicles to fix power steering; expects to take a charge of up to ~$750 mln in the first quarter, primarily for the cost of recall-related repairs).
Analyst comments: INVN -5.8% (downgraded to Perform at Oppenheimer), CLI -2.1% (downgraded to Hold from Buy at KeyBanc), MX -1.7% (downgraded to Neutral at Chardan Capital Markets), BGC -0.8% (downgraded to Neutral from Buy at DA Davidson), POT -0.6% (downgraded to Hold from Buy at Cantor Fitzgerald)